CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5) Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone Change in plasma volume and prognosis in acute decompensated heart failure: an observational cohort study Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure

Clinical TrialNov. 17, 2019

JOURNAL:Circulation. Article Link

Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial

MN Kosiborod, PJhund, KF Docherty et al. Keywords: dapagliflozin; HFrEF; quality of life; cardiovascular outcomes

FULL TEXT PDF